ImageVerifierCode 换一换
格式:PPT , 页数:17 ,大小:2.64MB ,
资源ID:14917842      下载积分:3 金币
快捷下载
登录下载
邮箱/手机:
温馨提示:
快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。 如填写123,账号就是123,密码也是123。
特别说明:
请自助下载,系统不会自动发送文件的哦; 如果您已付费,想二次下载,请登录后访问:我的下载记录
支付方式: 支付宝    微信支付   
验证码:   换一换

加入VIP,免费下载
 

温馨提示:由于个人手机设置不同,如果发现不能下载,请复制以下地址【https://www.bdocx.com/down/14917842.html】到电脑端继续下载(重复下载不扣费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: 微信登录   QQ登录  

下载须知

1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
2: 试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。
3: 文件的所有权益归上传用户所有。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

本文(循环肿瘤细胞最新进展PPT文件格式下载.ppt)为本站会员(b****2)主动上传,冰豆网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知冰豆网(发送邮件至service@bdocx.com或直接QQ联系客服),我们立即给予删除!

循环肿瘤细胞最新进展PPT文件格式下载.ppt

1、CD45(+)and CD66(+)lBasic modes:positive selection mode:anti-EpCAM negative selection mode:anti-CD45 anti-CD66 CTC-iChip systemCombines the strengths of microfluidics for rare cell handing and magnetic-based cell sorting.lMagnetic labeling of cells in blood cells.(pos-vs neg-)lDebulking by separation

2、 of nucleated cells from the enucleated.lAlignment of nucleated cells within a microfluidic channel.lDeflection of magnetically tagged cells into a collection channel.The Special conditions for CTC cultrueBlood samples:patients with metastatic ER(+)Nonadherent culture conditions(critical)Serum-free

3、supplemented EGF and FGFunder hypoxic conditions(4%O2)Establish long-term oligoclonal CTC(sustaimed in vitro 6months)Results of CTC culturel CTC lines can only be generated from patients who were either off therapy or progressing on treatment.and cannot be generated from patients who were responding

4、 to treatment.l For three patients,four additional CTC cell lines were established from blood samples drawn at multiple different time points during therapy.In these cases,CTCs were cultured only when patients were progressing on treatment.Results of CTC culturelCultured CTCs shared cytological feat

5、ures with the matched primary CTCs captured.lConsisitent with standard CTC definitions:CK(+);CD45(-);proliferative index30%(Ki67);initial doubling time:3days to 3weeks.lFive CTC lines retained ER(+),BRx-07 lost ER expresion,but regained in Xenograft tumor.lCTC-derived tumors shared histological and

6、immunohistochemical features with the matched primary tumor.Gene analysis lRNA sequencing analysis 6 cultured cell lines;13 commonly used breast cancer cell lines;29 unclured single CTCs.lMutation analysis SNaPShot:primary tumor(140 mutations in 25 gene)NGS platform:CTC culture and other mutation(10

7、00 genes)Results of gene analysisESR1(BRx-68),TP53(BRx-68,61)and KRAS(BRx-42)are universally present in all independent CTC cell lines.PIK3CA,KRAS and FGFR2 are arising mutations.The mutant allele frequences of TP53 and ESR1 are increased upon prolonged culture.Choose drug targets ESR1 and PIK3CA fo

8、r drug sensitivity test.Results of Drug Sensitivity testSome CTC drug sensitivity measurements were concordant with clinical history.Results of Drug Sensitivity(BRx-68)SERMs(tamoxifen)and SERD(raloxifene)were ineffective,alone or combined with inhibitors of PIK3-mTOR(everolimus).HSP90 inhibitor STA9

9、090 demonstrated cytotoxicity,alone or combinition with SERMs or SERD.A low dose of STA9090 suppressed ER level.?Results of Drug Sensitivity(BRx-07)Cultured CTCs were highly sensitive to PIK3CA and FGFR2 inhibitors.Combinations of PIK3CA and FGFR inhibitors showed cooperatove effects.?iIGFR mitigate

10、 sensitivity to iPI3K;iHSP90 stablize mutant kinases.Results of Drug Sensitivity(BRx-07)Different FGFR mutations have different sensitivity to PIK3CA and FGFR2 inhibitors.ConclusionsStudy patterns of drug susceptibility with CTC,combined with genetic context.Enable monitoring of emerging subclones with alterd mutational and drug sensitivity profiles.DiscussionlSamples:patients with metastatic/PVTT which stage?lMode:negative mode.lDrug targets:mutational gene analysis Liu Zixinwhich stage?biomarkers?AFP?

copyright@ 2008-2022 冰豆网网站版权所有

经营许可证编号:鄂ICP备2022015515号-1